Last reviewed · How we verify
Umbilical Cord Blood administration
Umbilical Cord Blood administration is a Biologic drug developed by MinYoung Kim, M.D.. It is currently in Phase 1 development. Also known as: Donated Umbilical Cord Blood Units from Affiliated Cord Blood Bank.
At a glance
| Generic name | Umbilical Cord Blood administration |
|---|---|
| Also known as | Donated Umbilical Cord Blood Units from Affiliated Cord Blood Bank |
| Sponsor | MinYoung Kim, M.D. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (PHASE1)
- Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal
- Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors (PHASE1)
- Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK) (PHASE1)
- Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances (PHASE1, PHASE2)
- Natural Killer-cell Therapy for Acute Myeloid Leukemia (PHASE1, PHASE2)
- Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC (PHASE1, PHASE2)
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Umbilical Cord Blood administration CI brief — competitive landscape report
- Umbilical Cord Blood administration updates RSS · CI watch RSS
- MinYoung Kim, M.D. portfolio CI
Frequently asked questions about Umbilical Cord Blood administration
What is Umbilical Cord Blood administration?
Umbilical Cord Blood administration is a Biologic drug developed by MinYoung Kim, M.D..
Who makes Umbilical Cord Blood administration?
Umbilical Cord Blood administration is developed by MinYoung Kim, M.D. (see full MinYoung Kim, M.D. pipeline at /company/minyoung-kim-m-d).
Is Umbilical Cord Blood administration also known as anything else?
Umbilical Cord Blood administration is also known as Donated Umbilical Cord Blood Units from Affiliated Cord Blood Bank.
What development phase is Umbilical Cord Blood administration in?
Umbilical Cord Blood administration is in Phase 1.
Related
- Manufacturer: MinYoung Kim, M.D. — full pipeline
- Also known as: Donated Umbilical Cord Blood Units from Affiliated Cord Blood Bank
- Compare: Umbilical Cord Blood administration vs similar drugs
- Pricing: Umbilical Cord Blood administration cost, discount & access